Titlebook: Chemotherapy of Fungal Diseases; John F. Ryley Book 1990 Springer-Verlag Berlin Heidelberg 1990 Chemotherapeutikum.Mykose.Pilzkrankheit.ch

jungle

Introductiond World War years, it was a relatively simple matter to get a compound active in an animal model of infection tested in humans. Toxicology was in its infancy and the disciplines of drug metabolism and pharmacokinetics embryonic. Some compounds became useful and established drugs, others just did not

分开

Mode of Action Studiesas been found on the basis of a truly rational approach. This may largely be explained by the unfortunate fact that fungi, like their human hosts, are eucaryotic organisms and hence the number of potential targets for specific drug action is limited. Furthermore, basic research on the biochemistry a

消息灵通

Pharmacokinetic Aspects of Antifungal Therapyication of the concepts of pharmacokinetics to the discovery and development of better therapeutic agents, particularly within the pharmaceutical industry, is growing rapidly. There are several aspects of this process which are particularly important in the development of antimicrobial agents. Thus,

oxidant

Customary

Formulationr clinical use since the nature of the formulation can have a considerable effect on the ultimate efficacy of the compound. It might be thought that oral treatment would present few problems, but with poorly soluble compounds such as griseofulvin or itraconazole, such factors as particle size or sol

跟随

懒洋洋

Clinical Trials directed at answering questions about the drug, is referred to as the conduct of clinical trials. Although most people would agree with this definition, one must predict that few other statements regarding aspects of clinical trials would result in uniformity of opinion. Indeed, if one were to plac

outset

Introductionthe unfortunate victims of fungal attack (as well as to generate more profit for their sustaining organisations!). The basic purpose of this section is not to teach clinicians how to do their job - though hopefully clinicians reading it will be stimulated to think again about their current attitudes

PSA-velocity

Therapeutic Considerations in Fungal Vaginitiso plague women throughout the world, and in most countries it is the most common cause of vaginitis. This is particularly the case in those countries with hot subtropical and tropical climates. In the USA, . vaginitis is the second most common cause of vaginal infection, surpassed only by bacterial

Inferior

An Infectious Disease Specialist’s Viewpointgent group of patients. Opportunistic fungal infections represent a significant cause of morbidity and mortality in the immunocompromised patient (.C. et al. 1981; . 1984; . 1987; . 1988). The more common fungi, ., ., and ., are not, however, the only agents responsible for this surge in the prevale